Evaluation of Safety and Systemic Pharmacokinetics After Single and Repeat Doses of Abicipar Pegol (AGN-150998) Intravitreal Injections in Patients With Neovascular Age-Related Macular Degeneration
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 05 Jul 2017
At a glance
- Drugs Abicipar pegol (Primary)
- Indications Wet age-related macular degeneration
- Focus Pharmacokinetics
- Sponsors Allergan
- 27 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 08 Dec 2016 Status changed from not yet recruiting to recruiting.
- 07 Oct 2016 Planned initiation date changed from 1 Aug 2016 to 1 Nov 2016.